First Trials Report Reveals Uneven State of China Drug Development
More Approvals But Fewer Completions
Executive Summary
Growing over 9% and domestic study sponsors take over 70% of the drugs in different stages, China clinical study sector attracts renewed interests post COVID, but underneath an uneven and less efficient field, noted a just released regulatory report.
You may also be interested in...
US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
China’s Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials
China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.
Setbacks For China Pharma As Firms Hit With Antitrust Fine, Clinical Setback
One of China's largest domestic pharma conglomerates has been fined more than $100m for price-fixing and other monopoly acts, while another firm has seen a major Phase III setback for its global launch hope.